文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

兰瑞肽对常染色体显性多囊肾病肾功能的影响:DIPAK 1随机临床试验

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

DIPAK 1开放标签随机试验纳入309例晚期ADPKD患者,比较兰瑞肽联合标准治疗与单纯标准治疗2.5年。两组eGFR年下降率无显著差异,兰瑞肽未延缓肾功能下降,但减缓了肾脏总体积增长,不良反应较常见。

要点

  • 晚期ADPKD患者使用兰瑞肽未显著延缓eGFR下降。
  • 兰瑞肽组肾脏总体积年增长率低于对照组。
  • 兰瑞肽组注射部位不适和腹泻等不良反应更常见。

核心结论

  • 在晚期ADPKD患者中,兰瑞肽联合标准治疗与单纯标准治疗相比,2.5年内未减缓肾功能下降。

研究设计与样本

  • 开放标签随机临床试验,终点评估采用盲法,2012年7月至2015年3月在荷兰4家肾脏病门诊纳入309例ADPKD患者。
  • 纳入标准为18至60岁、eGFR 30至60 mL/min/1.73 m2,随机分为兰瑞肽组153例和标准治疗组152例。

主要发现

  • 肾功能恶化发生率风险比0.87(95%CI 0.49至1.52;P=0.87)。

关键数值与推荐

  • 兰瑞肽用法为120 mg皮下注射,每4周一次,联合标准治疗。
  • 标准治疗目标血压<140/90 mm Hg。

临床怎么用

  • 研究结果不支持对晚期ADPKD患者使用兰瑞肽治疗。
  • 兰瑞肽组不良反应包括注射部位不适(32% vs 0.7%)、注射部位丘疹(5.9% vs 0%)、稀便(91% vs 6.6%)、腹部不适(79% vs 20%)和肝囊肿感染(5.2% vs 0%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function, eventually leading to a need for kidney replacement therapy. There are limited therapeutic management options. OBJECTIVE: To examine the effect of the somatostatin analogue lanreotide on the rate of kidney function loss in patients with later-stage ADPKD. DESIGN, SETTING, AND PARTICIPANTS: An open-label randomized clinical trial with blinded end point assessment that included 309 patients with ADPKD from July 2012 to March 2015 at 4 nephrology outpatient clinics in the Netherlands. Eligible patients were 18 to 60 years of age and had an estimated glomerular filtration rate (eGFR) of 30 to 60 mL/min/1.73 m2. Follow-up of the 2.5-year trial ended in August 2017. INTERVENTIONS: Patients were randomized to receive either lanreotide (120 mg subcutaneously once every 4 weeks) in addition to standard care (n = 153) or standard care only (target blood pressure <140/90 mm Hg; n = 152). MAIN OUTCOMES AND MEASURES: Primary outcome was annual change in eGFR assessed as slope through eGFR values during the 2.5-year treatment phase. Secondary outcomes included change in eGFR before vs after treatment, incidence of worsening kidney function (start of dialysis or 30% decrease in eGFR), change in total kidney volume and change in quality of life (range: 1 [not bothered] to 5 [extremely bothered]). RESULTS: Among the 309 patients who were randomized (mean [SD] age, 48.4 [7.3] years; 53.4% women), 261 (85.6%) completed the trial. Annual rate of eGFR decline for the lanreotide vs the control group was -3.53 vs -3.46 mL/min/1.73 m2 per year (difference, -0.08 [95% CI, -0.71 to 0.56]; P = .81). There were no significant differences for incidence of worsening kidney function (hazard ratio, 0.87 [95% CI, 0.49 to 1.52]; P = .87), change in eGFR (-3.58 vs -3.45; difference, -0.13 mL/min/1.73 m2 per year [95% CI, -1.76 to 1.50]; P = .88), and change in quality of life (0.05 vs 0.07; difference, -0.03 units per year [95% CI, -0.13 to 0.08]; P = .67). The rate of growth in total kidney volume was lower in the lanreotide group than the control group (4.15% vs 5.56%; difference, -1.33% per year [95% CI, -2.41% to -0.24%]; P = .02). Adverse events in the lanreotide vs control group included injection site discomfort (32% vs 0.7%), injection site papule (5.9% vs 0%), loose stools (91% vs 6.6%), abdominal discomfort (79% vs 20%), and hepatic cyst infections (5.2% vs 0%). CONCLUSIONS AND RELEVANCE: Among patients with later-stage autosomal dominant polycystic kidney disease, treatment with lanreotide compared with standard care did not slow the decline in kidney function over 2.5 years of follow-up. These findings do not support the use of lanreotide for treatment of later-stage autosomal dominant polycystic kidney disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01616927.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Meijer E, Visser FW, van Aerts RMM, et al. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial. JAMA. 2018. PMID: 30422235. doi:10.1001/jama.2018.15870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。